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ABSTRACT
Mechanisms of Reduced Vascular Tone Following Arteriogenesis Induced by Femoral Artery
Ligation

Chris Hatch

The presence of a developed, native collateral network can decrease the severity of ischemic
injury proceeding arterial occlusion. The collateral network must under arteriogenesis to enlarge
and increase blood flow to the ischemic region. Although there has been tremendous effort
attempting to understand the mechanisms of arteriogenesis, no therapies have been successful in
improving patient outcome. To better understand the mechanisms involved in arteriogenesis, the
effect of nitric oxide production, myogenic tone, and a-adrenergic receptors were evaluated as
these have been identified as playing an important role in vascular injury. Arteriogenesis was
induced by ligating the femoral artery between the epigastric and popliteal branches in male
C57/BL6 mice between two to four months old. Pharmacological agents were dissolved in a
physiological salt solution that was superfused over the exposed gracilis anterior to generate does
response curves. The collateral diameter was measured using intravital microscopy. Diameter
measurements were normalized to resting diameter to create percent changes for the operated
vessels and contralateral sham. Procedures were performed at both seven and twenty-eight days
following femoral artery ligation to evaluate how pathways changed with the restoration of
vascular tone. Nitric oxide production does not appear to play an important role as the values for
the day seven (-47 ± 7% for the operated and -43 ± 5% for the contralateral control) were similar
to day twenty-eight (-31 ± 5% vs -27 ± 4 %, control and operated respectively). Myogenic tone
does not appear to play an important role as the values for day seven (19 ± 3% for ligated and 31
± 7% for the sham) are similar to day twenty-eight (25 ± 3% vs 39 ± 6%, ligated and sham
respectively). a-adrenergic receptor stimulation appears to play an important role as there is a
heightened response at day seven (-71 ±7 % vs -39 ± 6%, ligated vs sham respectively)
compared to day twenty-eight ( -44 ± 4 % vs -31 ± 9%, ligated vs sham respectively). However,
inhibition did not appear to be significant because there is a lack of response at both day seven
(16 ± 9% vs 73 ±15 %, ligated vs sham, respectively) and day twenty-eight (16 ± 7% vs 50 ±7%,
ligated vs sham, respectively). These findings suggest that there is lack of sympathetic
innervation seven days after ligation that is restored twenty-eight days later.

Keywords: arteriogenesis, a-adrenergic receptors, endothelial nitric oxide synthase, L-type
voltage gated calcium channels, sympathetic innervation, vascular reactivity

iii

ACKNOWLEDGMENTS
I would like to thank Dr. Trevor Cardinal for providing me the opportunity to work on an
independent project in his lab throughout my undergraduate career. I would also like to thank
him for the countless hours he spent helping me develop scientific skills while working on this
project.
I would also like to thank all members of the Microcirculation and Vascular Regeneration Lab
for their continual support as colleagues and friends.
Many thanks to the Hannah Forbes Scholarship for funding this project.

“Hmmmmm”

iv

TABLE OF CONTENTS

Page
LIST OF FIGURES ..............................................................................................................

vi

INTRODUCTION ................................................................................................................

1

METHODS ...........................................................................................................................

6

Animals ......................................................................................................................

6

Femoral Artery Ligation ...........................................................................................

6

Solution Preparation ..................................................................................................

6

Superfusion ................................................................................................................

7

Perfusion Fixation......................................................................................................

7

Immunofluorescent Staining......................................................................................

8

Imaging .....................................................................................................................

8

Measurements and Statistics .....................................................................................

8

RESULTS .............................................................................................................................

9

DISCUSSION .......................................................................................................................

16

REFERENCES .....................................................................................................................

22

APPENDICES ......................................................................................................................

28

v

LIST OF FIGURES

Page
Figure 1. Peripheral Artery Disease .....................................................................................

1

Figure 2. Mechanisms of Arteriogenesis ..............................................................................

3

Figure 3. Regulation of Vascular Tone ................................................................................

5

Figure 4. Effect of Nitric Oxide on Collateral Growth .........................................................

10

Figure 5. Effect of Myogenic Tone on Collateral Growth ...................................................

11

Figure 6. Role of a-adrenergic Receptors in Collateral Growth ..........................................

14

Figure 7. Role of Sympathetic Innervation ..........................................................................

16

vi

Introduction
Peripheral artery disease (PAD) affects approximately 8.5 million people in the United
States and manifests as intermittent claudication, or pain while walking [National, Di Minno,
Criquie]. PAD is a type of ischemic disease caused by atherosclerosis of the lower extremities
[Allen], and the most severe form of PAD is critical limb ischemia (CLI) which effects roughly
11% of patients (figure 1) [Nehler]. CLI manifests itself as severe blockage in the arteries of the
lower extremities that results in ischemic rest pain, gangrene, and ulcer formation [Samura].
Approximately 20-30% of the individuals with CLI cannot receive the common treatments of
angioplasty or bypass due to comorbidities [Davies, Norgen]. As a result, about 20% of the CLI
patient population faces mortality within five years [Norgen]. Therefore, there is a need for
alternative therapeutic options to treat individuals with PAD or CLI that cannot receive the
common treatments.

Figure 1. Peripheral Artery Disease (PAD). PAD is the accumulation of plaque in the peripheral
circulation, typically in the lower extremities [Peripheral]
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The presence of collaterals, or natural bypasses around the occluded region, can mitigate the
severity of PAD [Annex] as increased collateral number is associated with improved functional
performance [McDermott, Keeling]. Arteriogenesis, collateral growth, is a response mechanism
to provide an ischemic region with sufficient blood flow by increasing the hemodynamic
capability of the collaterals (figure 2) [Yu]. Many groups have tried to stimulate arteriogenesis in
clinical trials by targeting the key processes involved. [Krishna, Annex, Raval, Maufus, Perin].
Arteriogenesis is caused by an increase in shear stress due to the occlusion that stimulates
structural wall remodeling in an attempt to normalize shear stress [Troidl, Mack]. Additionally,
the occluded vessel can create a hypoxic region downstream that leads to cells releasing proangiogenic cytokines and growth factors [Landázuri, Annex]. These growth factors and
increased shear stress mobilize progenitor and inflammatory cells from the bone marrow to enter
the surrounding tissue and start the process of arteriogenesis [Landázuri, Mack]. Numerous cells
and pathways have been targeted to develop therapeutic treatments stimulating arteriogenesis
[Krishna, Annex, Raval, Maufus, Perin]. The pro-angiogenic vascular endothelial growth factor
(VEGF) was regarded as one of the most likely candidates for treatment. VEGF induces
monocyte chemoattractant protein -1 (MCP-1) in endothelial cells (ECs) which leads to
monocyte recruitment, and it stimulates EC proliferation and migration [Jazwa, Schaper]. Other
approaches focused on colony stimulating factor, progenitor cells, and autologous bone marrow
derived mononuclear cells [Raval, Maufus, Perin]. Although there were promising results in
preclinical models, there has been no conclusive efficacy in larger human randomized clinical
trials [Krishna, Annex, Raval, Maufus, Perin].
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Figure 2. Mechanisms of Arteriogenesis. Increased shear stress leads to monocyte recruitment that stimulates
arteriogenesis [Schirmer]

Therefore, it might not be sufficient for these collaterals to reperfuse downstream tissue
by acting solely as larger conductance pathways because abnormal vascular reactivity might
limit the therapeutic effects of collaterals [Bauters]. Collaterals should also be able to regulate
blood flow to match oxygen delivery with tissue metabolic demand [Rey]. Normally, blood flow
is locally controlled to ensure sufficient oxygen to tissues. However, following ischemia, blood
flow is controlled by a high resistance collateral circuit that must have a functional range that can
accommodate varying levels of tissue metabolic demand [Taylor]. Therefore, it is interesting that
most investigators focus on maximum diameter measurements, which does not provide
information about the resting diameter and vascular reactivity, which define the ability of a
resistance vessel to regulate blood flow. [Gruionu, Heuslein, Clayton]. In order to develop new
therapeutic strategies, a greater understanding of the processes of vessel adaption is needed,
which can be accomplished by evaluating vascular reactivity [Jaipersad].
Although clinical observations in patients with PAD show a loss of vascular reactivity, there
is no consensus on the underlying mechanisms [Silva, Langham]. One explanation is endothelial
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dysfunction, as patients with PAD have greater endothelial dysfunction with impaired
vasodilation [Parshakov]. However, patients with PAD have significantly higher plasma NO
levels compared to non-PAD patients [Miralles], suggesting that the lack of vasodilation is
caused by insensitivity of SMCs to NO [Silva]. SMCs display both contractile and synthetic
phenotypes, each with diverse migration rates and protein expression [Rensen], and SMCs
switch between the two phenotypes based on environmental stimuli [Gomez]. A proinflammatory environment causes SMCs to transition into a synthetic, largely noncontractile
phenotype [Brozovich]. During arteriogenesis, there is an increase in regulator of G-protein
signaling 5 (RGS5), which terminates signaling cascades that control contractility of SMCs
[Arnold]. Both factors could affect the ability of SMCs to regulate vascular reactivity, which
would lead to reduced functionality. In newly formed collaterals of the mouse spinotrapezious
muscle, there is a loss of vascular reactivity via impaired vasodilation and lack of
vasoconstriction seven days after arteriogenesis begins, which is caused by a lack of SMCs
contractility. However, these are presumably new SMCs in the region, which might explain the
restoration of vascular reactivity at twenty-one days [Gouin III]. The lack of agreement on the
cause of a loss of vascular reactivity in PAD patients suggests the need to further examine the
basic mechanisms driving collateral remolding . If important signaling pathways can be
identified, better therapeutics might be developed [Heuslein, Jaipersad].
Vascular tone is regulated by vasoconstriction and vasodilation of the collaterals that include
many signaling pathways (figure 3) [Korthuis, Tykocki, Durand, Dora]. Myogenic tone, the
mechanism responsible for pressure-dependent, steady state contractility of SMCs, plays a
prominent role in regulating vascular tone [Jackson]. Specifically, L-type voltage Ca2+ channels
(LVCCs) are integral as they are major source of activator Ca2+ in myogenic tone [Tykochi].
Fluid shear stress regulates vascular tone by activating endothelial nitric oxide synthase (eNOS)

4

that creates NO [Iring]. NO then acts as a vasodilator of SMCs, thus regulating vascular tone
[Zhao Vascular nitric oxide]. Release of norepinephrine (NE) from sympathetic nerves targets aadrenoreceptors thus helping to regulate vasoconstriction [Calzada]. In a1-adrenoreceptors, NE
increases the inositol triphosphate (IP3) pathway which leads to an increase in intercellular Ca2+
and SMC vasoconstriction. On the other hand, in a2-adrenoreceptors, NE inhibits the adenylyl
cyclase (cAMP) pathway leading to vasoconstriction. Although there are other pathways, in
peripheral vascular disease these have been identified as being the most important [Frisbee].

Figure 3. Regulation of Vascular Tone. L-type Ca2+ channels increase SMC intercellular Ca2+ leading to increased
vasoconstriction. NE stimulates vasoconstriction. NO produced from shear stress leads to vasodilation

Previous work in the lab has demonstrated that arteriogenesis following femoral artery
ligation induces a loss of vascular tone that is restored at a later point in time [Chu]. The goal of
this work was to evaluate the signaling pathways that might be responsible for the loss.
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Methods
Animals: All procedures were performed according to a protocol approved by the
California Polytechnic State University Institutional Animal Care and Use Committee. Male
C57BL/6 mice (The Jackson Laboratory; Sacramento, CA) between two and four months were
used for all experiments. The mice were maintained on a twelve-hour light/dark cycle with ad
libetum access to food and water. Mice were housed in microisolator cages and provided nesting
material, plastic tube, and “housing”.
Femoral Artery Ligation: Chronic hindlimb ischemia was induced by ligating the femoral
artery between the epigastric and popliteal branches [Limbourg]. Animals were anesthetized in
an induction chamber with 5% isoflurane in oxygen flowing at 1L/min. Hair was removed using
depilated cream and skin was disinfected with chlorhexidine diacetate. Ophthalmic ointment was
applied to prevent corneal desiccation. Pre- and post-surgical buprenorphine analgesic (0.075
mg·kg-1) was administered and body temperature was maintained at 35°C through the use of a
temperature-controlled heat pad and rectal thermistor probe (CWE, Inc.; Ardmore, PA).
Following a skin incision above the neurovascular bundle in the hindlimb, the left femoral artery
was separated from the neurovascular bundle distal to the epigastric branch and proximal to the
deep femoral branch. The femoral artery was ligated with 6-0 silk suture. The incision site was
then closed with 7-0 polypropylene suture. A sham surgery was performed on the contralateral
hindlimb, in which the skin was exposed and the connective tissue overlying the femoral
neurovascular bundle was blunt dissected before skin closure. Mice recovered on a heat pad until
ambulatory.
Solution Preparation: The physiological salt solution (PSS, ~35oC, pH~7.4) was
composed of (in µM): NaCl 137, KCl 4.7, MgSO4 1.2, CaCl2 2, and NaHCO3 18. Nitric oxide
synthase inhibitor Nw-Nitro-L-arginine methyl ester hydrochloride (L-NAME, Sigma-Aldrich,
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Lot No: MKBV9596V) and norepinephrine (NE, Sigma-Aldrich, Lot No: BCBR1921V) were
dissolved at 10-3 M and stored at -20°C until the day of the procedure. Norepinephrine receptor
inhibitor (α1) prazosin (Cayman Chemical, Lot No: 0446327-23), (a2) rauwolscine (Cayman
Chemical), and calcium channel blocker nifedipine (Cayman Chemical) were dissolved at 10-3 M
and freshly prepared.
Superfusion: 7 or 28 days following femoral artery ligation, animals were prepared as
previously described. The gracilis muscle was exposed via skin incision and connective tissue
was removed. A trans-illuminating LED probe was placed under the hindlimb to allow
visualization of the primary collateral. 60 ml of PSS was placed in a syringe heater (custom
built) and deoxygenated with 5% CO2 - 95%N2. PSS was then passed over the exposed collateral
at ~35°C at ~2 ml/min for an equilibration period of at least thirty minutes. Resting images were
captured using an intravital microscope (Olympus BXFM) with a 10X objective (Olympus
LMPlanFL N) and a digital imaging software (QCapture Pro). Responses to pharmacological
agents were determined from 10-8 M to 10-4 M over a period of five minutes. The procedure was
repeated on the sham side; if necessary, the entire process was then repeated for additional
agents.
Perfusion Fixation: 7 or 28 days post-ligation, perfusion fixation was used to preserve
gracilis tissues. Before perfusion, gracilis anterior muscles were separated from surrounding
fascia to facilitate resection. After exposing the thoracic cavity, a 27G catheter was inserted into
the left ventricle via the apex of the heart, and the right atrium was cut to create an open system.
A 60 ml syringe loaded with a warm solution of 40 ml PBS containing 10-3 M Sodium
Nitroprusside, 10-4 M Adenosine, and 100 U/ml Heparin as an anticoagulant was perfused at
4ml·min-1 using a 10 ml syringe. Afterwards, animals were fixed with 5 ml of cold 4%
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paraformaldehyde. Once fixed, gracilis anterior muscles were resected from the profunda
femoris artery to the distal saphenous artery.
Immunofluorescent: Gracilis anterior muscles were whole-mount immunostained to visualize
vasculature (a-smooth muscle actin) and sympathetic innervation (tyrosine hydroxylase).
Following resection, muscles were incubated in 2% Triton-X-100 in 1X PBS for 2 hours at room
temperature. Muscles were then stained with 0.1% Triton-X-100, 2% BSA, 1:300 Anti-Actin asmooth muscle – Cy3 antibody mouse monoclonal (Sigma-Aldrich C6198), 1:1000 AntiTyrosine Hydroxylase Antibody (Millipore Sigma AB152) in PBS at 4°C for 96 hours. They
were then washed in PBS three times for 10 minutes at room temperature. Muscle were
incubated with 1:100 of secondary Goat anti-Rabbit IgG Cross-Adsorbed Secondary Antibody,
Alexa Flour 488 (ThermoFisher A11008) for 24 hours at room temperature and washed in 0.1%
Triton-X-100 in PBS three times for 10 minutes at room temperature followed by a 30 minute
wash in PBS at room temperature. Muscles were mounted on depression slides with 50/50
glycerol (Sigma G7757-1L) and PBS and stored in 4°C for one day before imaging.
Imagining: Whole muscles were imaged at 10X and 20X on an Olympus FV1000 confocal
microscope using the Alexa Fluor 488 and Texas red dye (594 nm) filter settings. Images were
captured using the Multi-Area Time-Lapse feature by identifying the region of interest using the
mosaic outline.
Measurements and Statistics: Vessel diameters were measured with Image/J software at
three different regions in the primary collateral. Differences between all concentrations and sham
and ligated sides were tested using repeated measured ANOVA followed by Tukey pairwise
comparisons. Percent change was calculated as the difference between a given time point and
resting diameter divided by resting diameter. All measurements are displayed as mean ± standard
error.
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Results:
The goal of this work was to identify signaling pathways that contribute to the restoration of
vascular tone following arteriogenesis. The three pathways that were evaluated were nitric oxide
production, myogenic tone, and a-adrenoreceptors because they have been identified as being
the most important in peripheral vascular disease [Frisbee].
The first pathway that was evaluated was NO production by inhibition with LNAME. Seven
days post femoral artery ligation the resting diameter on the ligated side was 83 ± 9µm with a
minimum diameter of 51 ± 5µm (Figure 4C). The contralateral sham had a resting diameter of 44
± 3µm with a minimum diameter of 30 ± 2 µm (Figure 4C). In order to gain greater clarity,
values were converted to percent change. The percent change normalized measurement to the
resting diameter, eliminating any bias from varying resting measurements. This translated to a
functional range of -47 ± 7% for the operated and -43 ± 5% for the contralateral control (Figure
4E). Twenty eight days later both the contralateral control and operated had similar percent
changes, -31 ± 5% vs -27 ± 4 %, respectively (Figure 4F). The operated side has a resting
diameter of 44 ± 3µm and a minimum diameter of 30 ± 2µm; whereas, the contralateral control
has a resting diameter of 33 ± 2µm and a minimum diameter of 24 ± 2µm (Figure 4D). Because
there is no statistical significance between the percent change at day seven and day twenty eight,
it is likely that NO production is not responsible for the loss of vascular tone and later
restoration.
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Figure 4. The effect of nitric oxide on collateral growth. NO does not appear to play a significant role in restoring
vascular reactivity. The representative images of the resting (A) and 10-4 M (B). There appears to be no significant
difference in vascular reactivity at either 7 days (C,E) or 28 days (D,F) post-femoral artery ligation. The difference
observed in the micron measurements is caused by an increased resting diameter on the ligated side * = p<0.05
between ligated and sham. % = p<0.05 between ligated day seven and day twenty-eight.

Because an excess vasodilating influence does not appear to be responsible, another
possibility was an insufficient vasoconstricting influence. Therefore, the second pathway that
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was evaluated was myogenic tone. Specifically, L-type voltage gated calcium channels (LVCCs)
were inhibited with nifedipine. tone. If myogenic tone played an important role, it would be
expected that there is a reduced influence of inhibition at day seven compared to day twenty
eight. Seven days following ligation the resting diameter of the ligated side was 86 ± 3µm with a
max diameter of 102 ± 2 µm. The sham side had resting diameter of 41 ± 3µm and a max
diameter of 53 ± 4µm (Figure 5C). This corresponds to a 19 ± 3% functional range for the
ligated side compared to a 31 ± 7% range for the sham (Figure 5E). Twenty eight days later, the
functional range for the ligated side remained relatively unchanged with a resting diameter of 70
± 6µm and a max diameter of 88 ± 7µm. The sham has a resting diameter of 39 ± 6µm and a
max diameter of 53 ± 6µm (Figure 5D). This produces a functional range of 25 ± 3% for the
ligated side compared to 39 ± 6% for the sham (Figure 5F). Because there is only one
concentration between both time points that is statistically different between the ligated and
sham, it is likely that the loss and restoration of vascular tone is not caused by LVCCs and
myogenic tone. Therefore, the hypothesis that myogenic tone plays a vital role is rejected
because there was not a reduced impact at day seven.
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Figure 5. Effect of myogenic tone on collateral growth. Myogenic tone does not appear to play an important role
in regulating vascular tone following arteriogenesis. The representative images at day seven between resting (A) and
10-4 M (B). There appears to be no significant difference in vascular reactivity at either 7 days (C,E) or 28 days (D,
F) post-femoral artery ligation. The difference observed in the micron measurements is caused by an increased
resting diameter on the ligated side. * = p<0.05 between ligated and sham. % = p<0.05 between ligated day seven
and day twenty-eight.

The third pathway that was evaluated was a-adrenergic receptors. In order to support a
hypothesis that VSMCs were in a state of proliferation, a minimal response to stimulation of aadrenergic receptors at day seven and increased response at day twenty-eight would be expected.
To test this, the receptors were stimulated with NE. At seven days post femoral artery ligation,
the collaterals on the operated side had a resting diameter of 78 ± 8µm and a minimum diameter
of 28 ± 5µm, while the contralateral control had a resting diameter of 48 ± 3µm with a minimum
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diameter of 30 ± 3µm (Figure 6C). The functional range of the operated side was -71 ± 7%
compared to -39 ± 6% for the sham, suggesting that VSMCs were hypersensitive to stimulation
(Figure 6E). However, at day twenty eight, vasoconstriction caused by NE was not statistically
different between the operated side and contralateral control, -44 ± 4 % vs -31 ± 9%, respectively
(Figure 6F). The resting diameter for the operated side at day twenty-eight was 46 ± 3µm and
the minimum diameter was 26 ± 2µm. The resting diameter for the contralateral sham was 33 ±
3µm with a minimum diameter of 23 ± 3µm (Figure 6D). This would suggest that VSMCs
phenotype is not responsible for the loss and restoration or vascular tone. Interestingly, it appears
that a-adrenergic receptors are hypersensitive to stimulation suggesting that there might be
insufficient NE signaling.
To evaluate the presence of a-adrenergic stimulation, prazosin, an a1-adrenergic
antagonist was applied to induce vasodilation. At day seven, prazosin reduced vascular tone in
the contralateral control significantly more than in the enlarged collateral, increasing diameter 73
±15 % vs 16 ± 9%, respectively (Figure 6I). The resting diameters for the resting of contralateral
sham and operated were 25 ± 2 µm and 47 ± 10µm, respectively. The maximum diameters were
44 ± 8µm and 53 ± 7µm, control vs operated, respectively (Figure 6G). This trend was consistent
at day 28 where the vasodilation between the operated and contralateral was significantly
different, 16 ± 7% vs 50 ±7%, respectively (Figure 6J). The resting diameter and max diameter
for the contralateral control were 28 ± 3µm and 42 ± 4µm, respectively. For the operated, the
resting diameter was 40 ± 3µm and the max diameter was 47 ± 6µm (Figure 6H).
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Figure 6. The role of a-adrenergic receptors in collateral growth. Stimulation, but not inhibition, of aadrenergic receptors appear to play a role in the restoration of vascular tone at day twenty-eight. Collaterals
demonstrate regional reactivity to a-adrenergic agonists at 7 days post femoral artery ligation as shown by the
difference between resting (A) and stimulation with 10-4 M NE (B). Collaterals appear to be hypersensitive to aadrenergic agonists at 7 days (C,E), but not 28 post femoral artery ligation (D,F). a-adrenergic antagonists appear to
be similar to contralateral sham at both time points (G-J). The difference observed in the micron measurements is
caused by an increased resting diameter on the ligated side. * = p<0.05 between ligated and sham. % = p<0.05
between ligated day seven and day twenty-eight.
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Figure 7. Role of Sympathetic Innervation in Arteriogenesis. Sympathetic innervation should play an important
role in arteriogenesis. a-smooth muscle actin (red) and tyrosine hydroxylase (red). There is significant background
noise/autofluorescence from the tissue. The entire gracilis anterior of unligated Balb/C at 10X magnification (A).
Midzone of gracilis anterior at 20X (B). Midzone at 20X with fewer z stacks of tyrosine hydroxylase to enable
viewing of innervation (C). Innervation is solid green surrounding collateral

Discussion
Femoral artery ligation is a viable model to study the loss and restoration of vascular tone
[Chu]. Seven days post femoral artery ligation there is an increased resting diameter and a
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decreased functional range that is restored at twenty-eight days [Chu]. It was hypothesized that
either nitric oxide (NO) production, myogenic tone, or a-adrenoreceptors were responsible for
causing this because these mechanisms were identified as being the most important in peripheral
vascular disease [Frisbee]. However, an increase in NO production is not a factor (Figure 4) as
inhibition of NO via LNAME had similar effects on both the sham and operated at both day
seven and day twenty-eight. Also, myogenic tone is not responsible for the restoration of
vascular tone (Figure 5) as there were no statistically significant trends in the percent change for
sham and operated at both time points. a-adrenoreceptors appear to play an important role in
regulating vascular tone following femoral artery ligation (Figure 6). At day seven, but not day
twenty-eight, there is increased sensitivity to stimulation of a-adrenoreceptors with NE (Figure
6).
It is unlikely that excess NO production from increased shear stress plays an important
role in the loss of vascular reactivity following collateral growth. There has been conflicting
results on the role of endothelial nitric oxide synthase and arteriogenesis. Systemic inhibition of
NO by treatment with LNAME from three to twenty-eight days after femoral artery resection led
to a decreased recruitment of vascular progenitor cells, specifically hemangiocytes
[Park/Hoffman]. Furthermore, this led to a decreased collateral diameter compared to mice
without inhibition, leading to the conclusion that NO is important in regulating arteriogenesis
during the first month following an ischemic event. [Park/Hoffman]. However, eNOS is
necessary for vasodilation immediately after femoral artery ligation, but not for collateral growth
[Mees]. In eNOS knockout mice blood flow is only decreased compared to wild type until day 7,
where afterwards they become similar [Mees]. Furthermore, a possible explanation for the
disagreement in literature is that more invasive and damaging methods, such as resection, might
induce both arteriogenesis and angiogenesis and thus might provide information that is not
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unique to arteriogenesis [Mees]. All of this would suggest that another pathway should play a
more prominent role.
Myogenic tone plays an important role in determining resting vascular tone in healthy
individuals [Howitt], and it has been hypothesized that SMCs phenotype switching relies on
suppression of L-type voltage gated calcium channels (LVCCs) [Wamhoff]. In a rat aortic
balloon injury, at day two and seven SMC proliferation increased and LVCCs were reduced
[Quignard]. However, LVCCs were restored by day thirty [Quignard]. This is not consistent with
the femoral artery ligation, as there appears to be no downregulation in LVCCs at either time
points (Figure 2). Interestingly, seven days post femoral artery ligation SMC proliferation peaks
(Bynum, unpublished). Therefore, it would be expected to see a loss of LVCCs influence at day
seven. A possible explanation is that an aortic balloon injury causes more damage than a femoral
artery ligation. This increased damage might correspond to greater SMC proliferation and thus
greater downregulation of LVCCs. However, a more likely explanation is that another pathway
plays a more prominent role. In other models, NO deficiency leads to T-type calcium channels
become more important in regulating vascular tone as shown by the ability to increase vessel
diameter greater than inhibition with LVCCs [Howitt]. Although it is unlikely there is NO
deficiency in arteriogenesis, this raises the possibility that other pathways that regulate myogenic
tone might become more important in regulating vascular reactivity. Transient receptor potential
cation channel subfamily V member 4 (TRPv4) activation enhances arteriogenesis, suggesting
that it might play a more prominent role in regulating vascular tone [Troidl, Schierling]. Inositol1,4,5-triphosphate receptors (IP3R) and ryanodine receptors (RyR) regulate intracellular Ca2+
concentration. During SMC proliferation there is a reduction in RyR, but not IP3R [Vallot].
After SMC differentiation, the number of RyR matches those found before proliferation [Vallot].
Evaluation of RyR receptors following arteriogenesis might provide insight into the role of
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myogenic tone in regulating vascular tone; however, it is challenging to find pharmacological
agents that selectively target these pathways in vivo [Tykocki].
Inhibition of a-adrenergic receptors is probably not responsible for the loss of vascular tone.
When only a-1-adrenegic receptors are inhibited following femoral artery occlusion there is no
change in the conductance of the collateral circuit [Taylor]. However, catecholamine synthesis
appears to play an important role in collateral vessel growth. When catecholamine synthesis is
knocked out via gene deletion of dopamine b-hydroxylase, there is reduced collateral vessel
growth [Chalothorn]. Furthermore, denervation upstream of the gracilis anterior before ligation
leads to impaired arteriogenesis as demonstrated by a decreased collateral diameter [Cen]. On the
other hand, stimulation of a-adrenergic receptors leads to increased SMC proliferation following
aorta balloon injury [Erami]. Although there was no change between inhibition of a-adrenergic
receptors at day seven and day twenty eight, there was an increased response to a-adrenergic
stimulation at day seven, but not at day twenty-eight that would imply stimulation of aadrenergic might be responsible for the restoration of vascular tone. Interestingly, this trend is
evident in patients with CLI, as there is increased vasoconstriction in ischemic skeletal muscle
compared to non-ischemic [Jarajapu]. Furthermore, a three hour acute ischemic condition in
canine femoral arteries showed not only increased contractility towards norepinephrine, but also
a decrease in prazosin and Rauwolscine induced vasodilation [Sapienza]. The increase in
vasoreactivity was caused by increased density and functional activity of a-adrenergic receptors
[Sapienza]. Therefore, it is possible that there is an increase in functional activity and density of
a-adrenergic receptors at day seven leading to increased hypersensitivity that is restored at day
twenty eight.
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On another note, the hypersensitivity of NE and reduced a-adrenergic receptor activity at day
seven could be symptomatic of a lack of sympathetic innervation. In rat soleus muscles there is
an increase in chemosensitivity following resection of the sciatic nerve in the thigh [Jones]. This
suggests that the hypersensitivity of NE at day seven could be caused by lack of innervation.
During arteriogenesis, MMPs degrade the tissue structure [Cai 2000]. We hypothesize that
during this remodeling the sympathetic innervation is either damaged or distances itself from the
collaterals. Following nerve crush, blood vessel diameter increases until nerve regeneration
leads to a greater regulation of vascular tone [Podhajsky]. Further support of this concept comes
from angiogenesis where vascularization precedes innervation As time proceeds, MMPs are
downregulated [Cai 2000], which could allow the sympathetic nerves to fully innervate
collaterals leading to greater regulation of vascular tone. Therefore, the restoration of vascular
tone that is seen at day twenty-eight likely correlates with an increase in vascular tone. A
possible way to evaluate this is to stain for sympathetic innervation and a-smooth muscle actin at
both day seven and day twenty-eight. In Balb/C mice, anti-tyrosine hydroxylase was used to
stain for sympathetic innervation (Figure 7). Some optimization is necessary before this stain can
be implemented. Furthermore, changing the secondary to a different wavelength, such as 647
nm, might remove the background noise from the tissue.
Interestingly, treatment with nerve growth factor (NGF) improves arteriogenesis by
increasing arteriole density [Emanueli]. In spite of this, there appears to be a lack of interest in
sympathetic innervation in clinical trials, possibly because there is no significant difference
between biomarker expression of NGF in healthy individuals compared to individuals with PAD
[Gardner]. Future studies could evaluate the role of Netrin-1 and arteriogenesis. Netrin-1 is an
axon guidance cue produced by SMCs that regulates arterial innervation, and a lack of Netrin-1
leads to defective vasoconstriction [Brunet]. Future studies could determine how Netrin-1
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expression changes during SMC phenotype switching to see if it might play a role in reinnervation of sympathetic neurons.
Ultimately, stimulation of arteriogenesis has the potential to be a therapeutic treatment for
PAD. Although there has been success in preclinical models, no treatment has had clinical
success, which points to the need for a greater understanding of the underlying mechanisms.
Evaluation of vascular reactivity has the potential to provide insight into novel therapeutic
options. There is a larger resting diameter and increased sensitivity to NE seven days post
femoral artery ligation, but by twenty-eight days post femoral artery ligation the resting diameter
has decreased and NE sensitivity is on par with the contralateral sham. This suggests that there is
a loss of sympathetic innervation at day seven that is restored at day twenty-eight. Therefore,
future therapeutics should target sympathetic innervation to improve patient outcome.
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Appendices: Protocols

Date ______________

Hindlimb Ischemia Surgery – Femoral Artery Ligation
____35.

Mouse Information
Age: _____________________
Sex: _____________________
Tag: _____________________
Genotype/strain: ____________
Cage: ____________________

____36.
____37.
____38.
____39.

Purpose: ___________________________________
___________________________________________

____40.

Materials

____41.

Pre-sterilize in autoclave
____1.
____2.
____3.
____4.
____5.
____6.
____7.
____8.
____9.
____10.

Standard pattern forceps (1)
Fine forceps- S&T (2)
Ultrafine forceps- 545 (1)
Curved iris scissors (1)
Microdissection scissors (1)
Gauze sponges- 2x2 and 4x4
Cotton swabs
6.0 silk suture (2 x 1-inch pieces)
7.0 prolene suture
Needle holder (1)

Obtain in surgery suite
____11.
____12.
____13.
____14.
____15.
____16.
____17.
____18.
____19.
____20.
____21.
____22.
____23.
____24.
____25.
____26.
____27.
____28.

Depilatory cream- Veet
Non-sterile cotton swabs
Non-sterile gauze sponges (2x2 and 4x4)
Chlorhexidene diacetate (Nolvasan)
1-mL insulin syringes (2)
Buprenorphine analgesic (0.03 mg·ml-1)
Ear punch
Veterinary ointment
Surgical tape
FST heat pad w/ rectal probe
Surgical scrubs
Sterile petri dish (1)
Sterile 5-mL syringe (1)
Sterile saline
Isolation mask and cap
Sterile gloves
Recovery bin and heat pad
70% isopropyl alcohol (IPA)

Animal preparation
____29.
____30.
____31.
____32.
____33.
____34.

Spray surgery area with Nolvasan.
Place animal in induction chamber.
Open oxygen cylinder. Set flow high and
isofluorane to 5%.
Once anesthetized, weigh animal and move
to preparatory bench in a supine position.
Reduce isoflurane to 1-3% and flow to 0.51.5 l·min-1.

____42.
____43.
____44.

Initials ___________

Apply depilatory cream to hindlimb with a
cotton swab and let sit for 1-3 minutes.
Spray a 2x2 gauze sponge with Nolvasan
and wipe hindlimb clean of cream and hair.
Flip animal over and apply ear punch.
Administer pre-op buprenorphine dose
(0.075 mg·kg-1) by subcutaneous injection.
Cover heat pad with a 4x4 gauze sponge and
transfer animal to surgery stage.
Apply lubricant to rectal probe and insert.
Set thermo-controller to 35°C.
Change into surgical scrubs and wash
hands/forearms.
Open sterile instrument tray and sterile pack.
Obtain sterile petri dish in sterile field and
fill with sterile saline, using a 5-mL syringe.
Put on mask, cap, and sterile gloves.

Surgery
____45.
____46.
____47.
____48.
____49.
____50.
____51.
____52.
____53.
____54.
____55.
____56.

Make a small incision on the middle, medial
aspect of the left hindlimb, directly over the
neurovascular bundle.
Extend incision to the abdominal wall
Blunt dissect subcutaneous connective tissue
to maximize surgical exposure.
Blunt dissect and retract epigastric fat pad to
expose ligation site, proximal to the
popliteal artery and distal to the epigastric.
Blunt dissect connective tissue over bundle
and separate nerve from the artery-vein pair.
Use ultrafine forceps to separate the artery
from the vein.
Tie off the femoral artery with silk suture.
Use 7-0 prolene suture to close the incision
with spiral sutures.
Make a small incision in the middle medial
aspect of the left hindlimb.
Extend incision to the abdominal wall
Blunt dissect subcutaneous connective tissue
to maximize surgical exposure.
Use 7-0 prolene suture to close the incision
with spiral sutures.

Post-Surgical
____57.
____58.
____59.
____60.
____61.

Administer post-op buprenorphine dose
(0.075 mg·kg-1) by subcutaneous injection.
Microwave recovery heat pad for ~1-2 min.
Transfer animal to recovery bin.
Turn off isoflurane, flow, and close oxygen.
Wipe down surgical area with IPA and wash
all instruments.

Gently apply veterinary ointment to eyes
using a cotton swab.
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Superfusion -Vascular Reactivity
Purpose: To specifically modulate different
pathways affecting vasoreactivity at increasing
doses on the sham and ligated side to evaluate how
arteriogenesis affects the underlining pathway
Safety Concerns:
• Check SDS and SOP for all pharmacological
agents.
• Be careful of residual heat from syringe
heater.
• Be careful of sharp edges instruments
• Dispose of mouse in carcass container
• Dispose of all waste in appropriate labeled
waste container
Materials:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.

Standard pattern forceps (1)
Fine forceps- S&T (2)
Curved iris scissors (1)
Depilatory cream – Veet
Cotton swabs
Gauze sponges (2X2 and 4X4)
Chlorhexidene diacetate (Nolvasan)
70% isopropyl alcohol (IPA)
Jelly
Surgical tape
FST heat pad w/rectal probe
Petri dish w/ PBS
Syringe Heater
10ml Graduated cylinder
Hot plate
5% CO2 – 95% N2 with tubing
Supefusion tubing
Vacuum pump evacuation flask
Physiological salt solution (PSS) (stock solution 20X
in 4oC
Sodium bicarbonate
Vasodilator/vasoconstrictor
Trans-illuminator
Intravial microscope – Qcapture Pro
Kim wipes
Plastic wrap
Petri dish
500ml beaker
60ml syringe (x2)
18 ohmic water
1 L volumetric flask
Instrument stand
Sodium nitroprusside (SNP)
1M Hydrochloric acid (HCl)

Instrument Preparation

34. Dilute sodium bicarbonate (20x) and PSS (20x) in 18
MW water using 1L volumetric flask
35. Pour ~300 ml in 500ml beaker and place on hot plate.
Turn hot plate on to ~85C
36. Place syringe heater on instrument stand and insert 2
60ml syringes in outside slots
37. Put stopcocks on 60ml syringes and connect tubing
38. Pour ~50ml in each 60ml syringe and turn syringe
heater on
39. Put aliquoted reagent in middle slot of the syringe
heater
Animal Preparation
40. Prepare animal for surgical exposure
Surgical Exposure
41. Bubble 5% CO2 – 95% N2 in 60 ml syringes and cover
with plastic wrap
42. Make a small incision on the middle, medial aspect of
the thigh
43. Extend the incision up the abdominal wall
44. Cut away the skin above the gracilis muscles and the
collateral circuit to expose the region from the
profundal to the saphenous
45. Very gently, blunt dissect and remove the connective
tissue overlying the gracilis muscle
46. Move surgical stage underneath the BXFM
47. Position the trans-illuminator LED probe underneath
the limb, below the gracilis
48. Open QCapture Pro and position the intravital
microscope above the collateral arteriole in the gracilis
anterior
Superfusion
49. Support superfusion tubing with instrument stand and
place over exposed gracilis muscles
50. Place a kim wipe that has been torn in half on top of
plastic wrap and roll it to make a wick. Place on top of
thigh (make sure not to touch muscle) and the other
end in a petri dish
51. Open stopcocks to syringe heater and check pH (7.27.4), flow rate (~2 ml min-1), and temperature (~35oC)
of PSS and keep running. Continuously check
throughout remainder of procedure
52. Allow muscle to stabilize (~30 minutes)
53. Use the vacuum pump to remove PSS from petri dish
as needed.
54. Add PSS to 60ml syringe as needed (roughly every 10
minutes) during the 30 minute rest period
55. Acquire resting diameter of collateral
56. Top of 60ml syringe with PSS
57. Place first dosage of reagent in appropriate 60ml
syringe (left or right depending on sham or ligated
side)
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Superfusion -Vascular Reactivity
58. Capture images at 5 minutes (or longer if need be (look
in literature or do pilot study))
59. Refill 60ml syringe
60. Place next dose of reagent in appropriate slot for 60ml
syringe
61. Repeat steps 66-68 until all concentrations have been
used
62. Quickly flush 60ml syringe with PSS to remove
residual pharmacological agents
63. Repeat on sham side
64. Repeat with additional pharmacological agents
65. Close stopclock and stop PSS flow
66. Put .6 ml 10-3 M SNP into 60ml syringe and superfuse
over exposed gracilis collateral. Image
Post Experiment
67. If perfuse fixing, fix mouse and remove gracilis
anterior
68. Perform Cervical dislocation to euthanize animal and
dispose of in bag and place in carcass box in -20C
freezer
69. Turn off isofluorane, flow, and close oxygen
70. Turn off hot plate
71. Flush superfusion line with 1M HCl and rinse with
distilled water
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Date ______________

Perfusion Fixation
____33.

Mouse Information
DOB: ___________________
Sex: ____________________
Tag: ____________________
Genotype/strain: __________
Cage: ___________________
Weight(g): _________________
Materials
Non-Sterilize Dissection Instruments
____1.
Forceps (1)
____2.
Fine forceps (2)
____3.
Bone scissors (1)
____4.
Curved Iris scissors (1)
____5.
Microdissection scissors (1)
____6.
Vascular clamp (1)
____7.
Castroviejos
Obtained in surgery suite
____8.
Tape
____9.
20 mL syringes (2)
____10. 5 mL syringe (1)
____11. Syringe pump
____12. Petri-dish
____13. Bench cover
____14. Depilatory cream
____15. Clippers
____16. Veterinary ointment
____17. Heating pad
____18. Catheter
____19. Non-sterile saline
____20. Cotton swabs
____21. Gauze sponges
____22. Saran wrap
Vasodilator Cocktail Preparation
____23. Turn on water bath to 37ºC
____24. 400 µL heparin
____25. 1mL SNP(orange)
____26. 600µL Adenosine(clear)
____27. 38mL PBS solution
____28. 5 mL 4% Paraformaldehyde (PFA)
____29. Thaw SNP, Adenosine and PFA
____30. Add heparin, SNP, Adenosine, and PBS
solution together in a 50mL conical
____31. Place vasodilator cocktail in water bath
Procedure Preparation
____32. Obtain saline filled petri-dish, cotton
swab, and instruments

____34.
____35.
____36.
____37.
____38.
____39.
____40.
____41.
____42.
____43.
____44.
____45.
____46.

____47.
____48.
____49.

Initials ___________
Remove hair on back by shaving &
depilation
Tape animal in supine position to 4X4
gauze sponge over heating pad
Expose muscles of interest and blunt
dissect to aid in removal post-fixation,
then cover with saran wrap
Fill 20mL syringe with 20 mL warm
Vaso D, load into syringe pump and
attach catheter
Flow liquid through the catheter to the
tip to prevent air from being injected
into circulatory system
Lift skin from muscle in abdominal
region and cut a window over the
sternum
Lift sternum and cut connective tissue
under
Use bone scissors in hole to quickly cut
through the ribs to the armpit on both
sides
Clamp sternum with castroviejos and
reflect towards mouse’s head
Cut diaphragm with curved iris scissors
to open chest cavity
Cut away excess tissue around the heart
Make a small incision in the apex of the
heart
Insert catheter and clamp with vascular
clamp and cut right atrium
Inject Vaso D solution into animal
approximately 2x 20mL (5mL/min),
soaking up excess blood and fluids with
gauze sponges
Inject 5 mL PFA (4 mL/min)
Dissect out muscles of interest using fine
forceps and microdissection scissors
Turn off water bath, cover scope, turn
off oxygen, turn off isofluorane, and
clean instruments

Notes
_________________________________________
_________________________________________
_________________________________________
_________________________________________
_________________________________________
_________________________________________

Fixation
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Date: ________

Whole Mount Immunofluorescent

Initials: _____

Purpose: To stain gracilis anterior muscles with a-smooth muscle actin and tyrosine
hydroxylase. This will provide insight into how innervation is impacted by arteriogenesis.
Materials:
• 24 well plate
• Phosphate Buffer Saline (PBS)
• TritonX-100 10% (Triton)
• Bovine Serum Albumin (BSA)
• Anti-Actin a-smooth muscle – Cy-3
antibody 1:300 (a-SMA) (C6198)
• Standard pattern forceps
• Glycerol

Methods:
• Place muscle in 2 ml centrifuge tubes
with 500 µL of 2% Triton in 1X PBS
and incubate at room temperature
(RT) for 2 hours shaking
incrementally
• Place muscle in 600 µL
microcentrifuge tubes with 300 µL of
0.1% Triton, 2% BSA, 1:300 a-SMA,
1:1000 THir in 1X PBS
• Wrap 24 well plate in aluminum foil
and incubate at 4°C for 96 hours.
Cover everything in foil from here on
out
• Wash in PBS 3X for 10 minutes at RT

•
•
•
•
•
•
•

•
•
•
•
•
•

Anti-tyrosine hydroxylase antibody
1:1000 (THir) (AB152)
Alexa 488 goat-anti rabbit 1:100
(secondary) (A11008)
Glass cover slips
Depression slides
Aluminum foil
Cover slips
Nail polish

Incubate with 1:100 secondary for 24
hours at RT
Wash in 0.1% Triton in PBS 3X for
10 minutes at RT
Wash in PBS for 30 min at RT
Place muscle on depression slide.
Using transfer pipet drip 1 to 2 drops
of 50/50 glycerol PBS on muscle
Place cover slide and paint edges with
nail polish
Store in 4°C and wait at least 1 day
before imaging

Notes:
______________________________________________________________________________
______________________________________________________________________________
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